Rise in Geriatric Population will Fuel Expansion of Global Nurse Call Systems Market at 13.90% CAGR

A new Transparency Market Research report states that the global nurse call systems market stood at US$0.6 bn in 2013 and is anticipated to reach US$1.6 bn by 2020. It is expected to expand at a CAGR of 13.90% from 2014 to 2020. The title of the report is “Nurse Call Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.”

Get a Free Sample Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2173

According to the report, factors such as the rising aging population and the growing need for responsive and efficient healthcare communication are amongst the major factors propelling the growth of the market for nurse call systems. In addition, the globally rising budget allocation in healthcare for elderly people is also a prime factor augmenting the growth of the market. In addition, the rise of the Internet of Things (IoT) within healthcare infrastructure has emerged as a key opportunity in the market. On the other hand, government regulations on distribution and manufacturing of nurse call systems are amongst the major factors impeding the growth of the market.

In terms of equipment type, the market is segmented into nurse call intercoms, nurse call buttons, nurse call integrated communication systems, and nurse call mobile systems. Amongst these, the segment of nurse call integrated communication systems led the market in 2013. On the other hand, the segment of nurse call mobile systems is predicted to expand at the highest growth rate in the forecast horizon owing to the rising demand for mobile solutions.

On the basis of communication technology, the report segments the market into wireless communication equipment and wired communication equipment. Amongst these, wired nurse call communication equipment dominated the market for nurse call systems in 2013. On the other hand, the demand for wireless nurse call communication equipment is poised to rise in the forecast horizon owing to the rising demand for flexibility and mobility in communication.

On the basis of end use, the nurse call systems market is segmented into OPD clinics, hospitals, ambulatory services, and assisted living centers. Amongst these, in 2013, the segment of hospitals constituted a share of approximately 74% in the market on the basis of revenue. On the other hand, factors such as the requirement for effective communication systems and patient safety will raise the demand for nurse call systems within the segment of assisted living centers in the forecast horizon.

Geographically, the market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, in 2013, North America held the largest share in the market on the basis of revenue. This is due to the rising adoption of nurse call systems within this region in numerous healthcare settings. Europe trailed North America and stood as the second largest market for nurse call systems on the basis of revenue in the same year. However, the market for nurse call systems is poised to experience sluggish growth in this region in the coming years owing to slow economic growth.

The chief players dominant in the market are Rauland-Borg Corporation, Stanley Healthcare, Hill-Rom Holdings, Inc., Tyco SimplexGrinnell, Ascom Holding AG, Cornell Communications, Inc., Azure Healthcare Limited, Jeron Electronic Systems, Inc., and Vigil Health Solutions, Inc., among others.

Full Research Report on Global Nurse Call Systems Market: 
http://www.transparencymarketresearch.com/nurse-call-system-equipment-market.html

Disruptive Behavior Disorders Market Growth Drivers 2023

Transparency Market Research provides a thorough analysis of the global disruptive behavior disorders market through its new research report. The report, titled “Disruptive Behavior Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” assesses the factors driving the overall market and the ones restraining it. The researchers have used a SWOT analysis to highlight the strengths, weaknesses, opportunities, and threats impacting the segments of the overall market. Additionally, the document also includes a trajectory of the global disruptive behavior disorders market by analyzing several journals, new articles, and research papers.

Get Free Sample Research Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4752

Disruptive behavior disorders are characterized by adamant and unfriendly behavior, which becomes an impediment to the normal functioning of the individual. Persons suffering from these disorders exhibit temper tantrums, physical aggression, excessive disagreement, depression, poor attention span, and other symptoms that borderline resistance towards regular activities and people. Oppositional defiant disorder (ODD) and conduct disorder (CD) are the two main branches of disruptive behavior disorders, which show prominent abnormal social skill sets and an inability to function in regular circumstances. Undiagnosed disruptive behavior disorders can intensify symptoms, posing as a serious harm to the patient’s life and to those around them.

The global disruptive behavior disorders market has been assessed on the basis of therapeutics and geography. The therapeutics segment is further divided into target molecules, administration, and mechanism of action and safety of the drugs. SPN-812, SUVN-502, AZ-5213, and ORADUR-ADHD are some of the drugs under investigation in the overall market. Geographically, this market is segmented into Asia Pacific, North America, Europe, and Rest of the World.

The global disruptive behavior disorders market is being driven by the rise in the number of comorbid disorders, which can be exceptionally dangerous, if untreated. Furthermore, the increasing investments made by pharmaceutical companies to develop effective drugs and therapeutics are also expected to propel this market in the coming years. However, the poor rate of diagnosis and the improper approaches towards treatments are likely to restrain the growth of this market in the coming years.

Some of the key players in the global disruptive disorders market are Eli Lilly and Co., Pfizer, Inc., Johnson & Johnson, DURECT Corporation, Bionomics Ltd., and Chelsea Therapeutics, Inc. The research report profiles these players to provide the competitive landscape of the global market and explain the nature of expansion styles used by these players to gain a competitive edge. Furthermore, the research report also evaluates the financial overview, research and development strategies, business and marketing strategies, and strategic mergers and acquisitions of these companies for the coming few years.

Full Research Report on Global Disruptive Behavior Disorders Market: 
http://www.transparencymarketresearch.com/disruptive-behavior-disorders-market.html

3D Bioprinting Market Demand in Medical and Healthcare Sector

A new study by Transparency Market Research (TMR), titled “3D Bioprinting Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024,” states that the increasing application of 3D bioprinting technology in the medical and healthcare sectors across the world is the key driver of the worldwide market.

Get a Free Sample Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11657

Apart from this, the increasing lifespan of individuals, the rising prevalence of chronic illnesses, the growing demand for tissue and organ transplants, the integration of information technology into the medical and healthcare sector, dearth of organ donors, advancements in 3D printing technology, and the augmenting base of the geriatric population are also driving the worldwide market for 3D bioprinting significantly, states the research study.

The report has also discussed the prospects of the global 3D bioprinting market at length. As per the study, the increasing requirement of regenerated tissues, organs, implants, and prosthetics are likely to present a lucrative opportunity for market players during the forecast period. In addition to this, the emergence of 3D bioprinted pills is projected to open new avenues for them in the coming years. The augmenting need for customized medicines and the rapid rise in the production of biodrugs are also anticipated to drive the market in the near future.

According to the report, the global market for 3D bioprinting is spread across Asia Pacific, North America, Europe, and the Rest of the World. North America leads the worldwide market in terms of revenue. The presence of an advanced medical and healthcare infrastructure, a large pool of chronically ill patients, and high spending power of people in this region is boosting the North America 3D bioprinting market significantly.

Analysts predict this regional market to retain its dominance during the forecast period, owing to continual research activities in the area of 3D printing. However, Asia Pacific is likely to surface as a strong contender for leadership in the global market for 3D bioprinting in the coming years. 

The rapid rise in the adoption advanced technologies, advancements in healthcare IT, favorable government initiatives, increasing foreign investments, and the growing awareness regarding 3D bioprinting technology are anticipated to propel the Asia Pacific 3D bioprinting market over the forecast period, states the report.

The research report has also analyzed the profiles of major companies operating in the global 3D bioprinting market and determined the current market hierarchy. Oceanz, Organovo Holding Inc., Luxexcel Group BV, TeVido BioDevices, Stratasys Ltd., Voxeljet, Solidscape, Aspect Biosystems, Materialise NV, Bio3D Technologies Pte Ltd., Cyfuse Biomedical, 3Dynamics Systems, BioBots, and Envision TEC are some of the key market players mentioned in this study.

Usage in Companion Diagnostic Services Stimulates Global Transcriptomics Market to Reach US$4.6 Billion by 2019

Transparency Market Research, a global market intelligence consultancy, has published a market study on the global transcriptomics technologies market for the 2013-2019 period. According to this report, the global transcriptomics technologies market will rise at a CAGR of 15.90% from 2013 to 2019 to reach a valuation of US$4.6 bn by the end of the forecast period. The market’s valuation in 2012 was US$1.65 bn. The report is titled “Transcriptomics Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”.

Get Free Sample Research Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1659
 
The report says that the global transcriptomics technologies market will witness substantial growth in the coming years due to several reasons. Transcriptomics research involves studying the structure and function of RNA present in a cell.Presently, transcriptome analysis of several organisms is assisted using next-generation sequencing platforms in the preliminary phase followed by polymerase chain reactions, gene regulation technologies, and microarrays in the latter part. The coalition of these technologies is used for drug discovery, clinical diagnosis of diseases, medical research, and others. With the ever-increasing demand for targeted therapeutics and continual improvement of healthcare infrastructure, the commercial usage of transcriptomics technologies holds promise. Transcriptomics research allows the development of newer therapeutics and diagnostics and further advancement of the existing line of treatment for medical conditions.

The report says that in the transcriptomics technologies market, the key application segments undergo consistent development in order to offer added value to users. For instance, the utilization of transcriptomics technologies has benefitted the pharmaceutical and biotechnology fields; other fields are also deriving the advantages of this technology for mutual benefits of both the technology and the application field. Laboratories attempting to use biomarkers and newer gene sequencing methods is an example of this.

The need for the development of adequate equipment in healthcare organizations and laboratories, the growing awareness about transcriptomics technologies globally, and increased participation of government bodies in transcriptomics research are some other factors driving this global market.

However, growth of the transcriptomics technologies market is hampered due to certain factors cited in this report. These include the unavailability of advanced equipment needed for biological computation, unavailability of services essential to analyzing complex information, and an overall deficit of technicians that have expertise in the subject.

The report divides the global transcriptomics technologies market into the regional segments of North America, Asia Pacific, Europe, and Rest of the World. Among the regional segments, Asia Pacific will exhibit a substantial uptake of these technologies and the fastest growth rate in the transcriptomics technologies market during the forecast period. Ongoing infrastructural development for improved healthcare and increased acceptance of novel biotechnology research are the reasons for this.

In 2012, North America led the global transcriptomics technologies market, contributing more than 35% of the revenue in the global market. The presence of advanced healthcare infrastructure, which includes well-equipped research facilities, increased awareness of biotechnology research, and the high number of initiatives taken by governments to promote research activities are the reasons for the dominant position of North America in this market.

The report mentions the top players that operate in the global transcriptomics market. These are Life Technologies Corporation, F-Hoffmann La Roche Ltd., Thermo Fisher Scientific, Illumina Inc., Agilent Technologies, and Affymetrix Inc.

Full Research Report on Global Transcriptomics Technologies Market: 
http://www.transparencymarketresearch.com/transcriptomics-technologies-market.html

Global Upper Respiratory Tract Disorder Diagnostics and Therapeutics Market

Respiratory disease is a medical condition that includes pathological conditions that affect tissues and organs which assist in making gas exchange possible in the organisms. Respiratory disease ranges from self-limiting and mild, such as the common cold, to life-threatening conditions such as lung cancer, pulmonary embolism and bacterial pneumonia. Various respiratory disease conditions include disorder of upper respiratory tract, bronchi, bronchioles, trachea, pleura and pleural cavity, alveoli, and the nerves and muscles of breathing.

Get a Free Sample Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3114

Upper respiratory tract disorder or infection (URI or URTI) is a medical condition caused by acute infection that involves upper respiratory tract such as sinuses, nose, larynx or pharynx. Pharyngitis, tonsillitis, sinusitis, laryngitis, common cold, and otitis media are some of the most common upper respiratory tract disorders. Upper respiratory tract disorders are caused by direct invasion of the mucus membrane (inner respiratory tract lining) by bacteria or virus. Rhinorrhea, sneezing, nasal congestion, nasal discharge, sore throat, cough, fever, odynophagia and malaise are some of the most common symptoms observed in the patient diagnosed with upper respiratory tract disorder. Some other symptoms of the disease are headache, foul breath, hyposmia, sinus pain, shortness of breath, conjunctivitis, vomiting diarrhea, nausea, and body ache.

Upper respiratory tract disorder can be diagnosed by physical examination, laboratory tests and review of symptoms. In physical examination, physicians look for redness and swollen inside the wall of nasal cavity, white secretions on the tonsils, redness of the eyes, redness of the throat, and enlarged lymph nodes around neck and head. Laboratory testing is usually not performed for examining upper respiratory tract disorders as most of the upper respiratory tract infections are caused by viruses and no specific treatment for different types of viral upper respiratory tract disorder is available in current scenario. Some of the laboratory tests that are performed for diagnosing upper respiratory tract disorder include imaging tests (X-ray and CT scan), blood tests and sputum tests.

Upper respiratory tract disorders can be treated with antibiotics and decongestants. Acetaminophen, ibuprofen, diphenhydramine, dextromethorphan, codeine, guaifenesin, dexamethasone and prednisone are some of the antibiotics that are prescribed to the patients suffering from upper respiratory tract disorders. Oxymetazoline, phenylephrine and pseudoephedrine are some of the most commonly prescribed decongestants for the treatment of upper respiratory tract disorders. Antibiotics are rarely used as a treatment option for upper respiratory tract disorders as they are associated with many side effects and also can initiate secondary infections and bacterial resistance.

The market for upper respiratory tract disorder diagnostics and therapeutics is expected to grow at a significant CAGR during the forecast period from 2014 to 2020 owing to increasing incidences of respiratory disorders across the globe. Similarly, constant changing climate condition due to global warming and pollution has further accentuated the risk for developing upper respiratory tract disorders. This in turn is expected to drive the growth of upper respiratory tract disorder diagnostics and therapeutics market. Currently, North America accounts for the largest share of the global upper respiratory tract disorder diagnostics and therapeutics market. This is due to the fact that the U.S. has witnessed for large patient pool suffering from upper respiratory tract disorders. 

Some of the major players operating in upper respiratory tract disorder diagnostics and therapeutics market include Alcon, Inc., Merck & Co., Inc., Collegium Pharmaceutical, Inc., GlaxoSmithKline plc and Verona Pharma Plc among other significant players across the globe.

Full Research Report on Global Upper Respiratory Tract Disorder Diagnostics and Therapeutics Market: 
http://www.transparencymarketresearch.com/upper-respiratory-tract-disorder-diagnostics-therapeutics.html

M2M Connected Healthcare Market: Global Industry Trends and Forecast 2014 - 2020

Over the past few years, the healthcare industry has been witnessing increasing adoption of machine to machine (M2M) technology in order to reduce skyrocketing healthcare costs,   increase adherence to medical regimens and improve better patient care. M2M connected healthcare is a healthcare delivery model that operates in an IT ecosystem, and allow easy access and sharing of healthcare related data such as patient medical history data, patient personal information, prescription information, diagnostic results, clinical data and others. Home monitoring, clinical monitoring, assisted living and telemedicine are among the major functions carried out by M2M connected healthcare systems. M2M connected healthcare saves time by connecting patients, healthcare providers and treatment systems over the internet. The M2M connected healthcare systems can use wired or wireless connectivity to share healthcare data between web-connected devices without the need of human involvement.

Get a Free Sample Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6928

The global market for M2M connected healthcare has been segmented into home monitoring, clinical monitoring, clinical trials, telemedicine, assisted living, worried well and clinical remote monitoring. Significant advantages associated with M2M connected healthcare have been identified as the major factors driving the M2M connected healthcare market growth. These advantages include reduced time, reduced healthcare cost, easy sharing of healthcare data and remote healthcare monitoring. M2M model also enables patients with more control over their treatment regime. Globally rising incidences of various chronic diseases such as diabetes, cancer and hypertension are also expected to play a key role in driving the market growth during the forecast period from 2014 to 2020. Persistent rise in geriatric population directly impacts the growth and development of connected health M2M services as elderly population is highly susceptible to acquire several health disorders as compared to younger adults. According to World Health Organization (WHO) projections, in 2010, global geriatric population was around 524 million and is anticipated to reach around 1.5 billion by the year 2050. Thus, a consistent rise in geriatric population would boost the growth of M2M connected healthcare market as they will increasingly seek M2M connected health services. One of the major factors that are expected to affect the market growth is that stake holders should have access to internet connection.

In terms of geography, the global market for M2M connected healthcare has been segmented into four major regions, namely, North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). North America represented the largest regional market for M2M connected healthcare in 2013. Well established healthcare infrastructure of the North American countries U.S. and Canada, and presence of a large pool of technically-savvy patient population are among the major factors responsible for North America’s leading position in this market segment. Europe represented the second largest market after North America. Germany, France, United Kingdom, Italy and Spain are the most potential markets in the European region that accounted for more than 60% of the overall Europe M2M connected healthcare market. During the forecast period from 2014 to 2020, APAC is expected to witness significant growth as M2M connected healthcare model will help in serving patients residing in remote area, overcoming distance barriers.

Allscripts, IBM, Apple, AirStrip Technologies, Cisco Networks, Microsoft, AT&T, BL Healthcare, Ingenious Med, NeuroVigil, PharmaSecure, QxMD Software, WellDoc and ObTech Medical are among the major players operating in this market. These players are competing with each other in order to get competitive advantages over others.

Full Research Report on Global M2M Connected Healthcare Market: 
http://www.transparencymarketresearch.com/m2m-connected-healthcare-market.html

Psoriatic Arthritis Pharmacotherapy Market Segment Forecasts up to 2020, Research Reports

Psoriatic Arthritis is a type of chronic inflammatory arthritis that primarily affects toes and fingers followed by nail or skin psoriasis. The clinical features are varied but the major symptoms are peripheral arthritis, enthesitis, psoriasis, dactylitis and axial disease. According to Arthritis Foundation, the prevalence of psoriatic arthritis in patients suffering from psoriasis is approximately between 7% and 48%. Psoriatic arthritis appears most often between the age of 30 years and 50 years. The factors contributing to the pathogenesis of psoriatic arthritis are genetic factors, environmental factors and immunological factors. Genetic factors explain that 40% of the psoriatic arthritis has family history of skin and joint diseases. Environmental factors such as bacterial and viral infections have been implicated as a cause in psoriatic arthritis. Immunological factors consist of cytokines such as TNF-α which is critically involved in inflammatory process, leading to bone and cartilage degradation as well as skin inflammation. There are five different types of psoriatic arthritis that includes different joints and spinal column. There are two types of method by which psoriatic arthritis is diagnosed by imaging and laboratory test. Imaging tests consist of X-Rays and magnetic resonance imaging and laboratories consists of rheumatoid factor and joint fluid test.

Browse Full Report with TOC @
http://www.transparencymarketresearch.com/psoriatic-arthritis-pharmacotherapy.html

The pharmacotherapy of psoriatic arthritis consists of drugs such as DMARDs (disease modifying anti-rheumatic drugs), NSAIDs, Immunosuppressant and TNF-α inhibitors. In chronic conditions surgeries and other procedures are practiced such as steroid injections and joint replacement surgery. The DMARDs consists of drug that reduces the progression of psoriatic arthritis and protect joints and other tissues from irreversible damage, it includes drugs such as methotrexate, sulfasalazine and leflunomide. The NSAIDs help to relive the pain and reduction of inflammation and most of them are OTC drugs including Ibuprofen and naproxen sodium. While immunosuppressant helps to control the immune system including azathioprine and cyclosporine. TNF-α inhibitors assist reducing pain, swollen joints and morning stiffness this class of drug includes etanercept, infliximab, adalimumab, Humira, certolizumab and golimumab.

Some of the major factors driving the psoriatic arthritis market are rising geriatric population, increasing incidences of psoriatic arthritis and major onset for growth in this market is expected from the launch of blockbuster drugs such as Simponi and Vicodin along with many impending biologics that are in late stage of development. The major factors restraining the growth of psoriatic arthritis pharmacotherapy market are the new biologics that are observed to be highly efficient but come with high cost. Lack of patient awareness is one of the major factor affecting the growth of psoriatic arthritis pharmacotherapy market according to CDC (Center of Disease Control and Prevention) nearly 10% - 12% of the patients visit clinics during the chronic stage of psoriatic arthritis as most of them ignore initial symptoms which are very common like skin reddening along with a joint pain or a skin rash.

North America was observed to be the leading geography due to high prevalence of psoriatic arthritis followed by availability of modern healthcare facilities is assisting the growth of this market. Europe is the second largest market for psoriatic arthritis pharmacotherapy as it’s the region expected to observe rapid aging population. Asia-Pacific and Rest of the World are the most attractive and growing markets in psoriatic arthritis pharmacotherapy. In Asia-Pacific China, India, Japan, South Korea and Australia are observed to be the leading geographies in psoriatic arthritis.

The psoriatic arthritis pharmacotherapy market is predominantly led by the players such as Pfizer, Inc., Amgen, Inc., Merck & Co, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Abbott Laboratories and Novartis International AG. It was observed that Abbott Laboratories, Johnson and Johnson and Amgen, Inc. account for the major market share in psoriatic arthritis pharmacotherapy.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

• North America
• Asia Pacific
• Europe
• Middle East and Africa
• Latin America

This report provides comprehensive analysis of

• Market growth drivers
• Factors limiting market growth
• Current market trends
• Market structure
• Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Read More Reports on Pharmaceutical Market: 

http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About us

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Inquiry Before Buying: 

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1065

Latest Press Release Reports: http://www.transparencymarketresearch.com/press-releases.htm

Latest Articles Reports: http://www.transparencymarketresearch.com/articles.htm

Contact Us

Mr. Nachiket Ghumare
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States.

Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Browse market research blog:
https://pharmaceuticalmarket.wordpress.com/